ADiTx Therapeutics Inc. (ADTX): Price and Financial Metrics

ADiTx Therapeutics Inc. (ADTX): $0.29

0.02 (+6.97%)

POWR Rating

Component Grades













Add ADTX to Watchlist
Sign Up

Industry: Biotech



in industry

ADTX Stock Price Chart Interactive Chart >

Price chart for ADTX

ADTX Price/Volume Stats

Current price $0.29 52-week high $3.95
Prev. close $0.27 52-week low $0.24
Day low $0.26 Volume 222,600
Day high $0.30 Avg. volume 623,387
50-day MA $0.36 Dividend yield N/A
200-day MA $0.92 Market Cap 12.97M

ADiTx Therapeutics Inc. (ADTX) Company Bio

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

ADTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ADTX Latest Social Stream

Loading social stream, please wait...

View Full ADTX Social Stream

Latest ADTX News From Around the Web

Below are the latest news stories about Aditxt Inc that investors may wish to consider to help them evaluate ADTX as an investment opportunity.

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

RICHMOND, Va., January 18, 2022--Aditxt, Inc. ("Aditxt," or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity’s transition to the "Age of Immunity," has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body’s immune response to COVID-19.

Yahoo | January 18, 2022

Aditxt, Inc. to Participate in Edison Group’s Global Healthcare "Open House" Virtual Conference From January 25th-27th, 2022

RICHMOND, Va., January 14, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.

Yahoo | January 14, 2022

Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO

RICHMOND, Va., January 12, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.

Yahoo | January 12, 2022

Lifshitz Law Firm, P.C. Announces Investigation of Aditxt, Inc. (ADTX)

NEW YORK, NY / ACCESSWIRE / December 31, 2021 / Lifshitz Law Firm, P. is investigating possible breaches of fiduciary duty by the board of directors of Aditxt, Inc.

Yahoo | December 31, 2021

Halper Sadeh LLP Investigates LAWS, ADTX, EPAY, SKIL, HXOH; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | December 30, 2021

Read More 'ADTX' Stories Here

ADTX Price Returns

1-mo -10.66%
3-mo -20.61%
6-mo -75.42%
1-year -89.68%
3-year N/A
5-year N/A
YTD -45.91%
2021 -74.23%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7019 seconds.